ENTA logo

Enanta Pharmaceuticals, Inc.

ENTA
Healthcare|Biotechnology|US
$11.00
+0.92 (+9.13%)
Tangible Book / Share
$3.47
Cash / Share
$6.51

About

Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.

Stock Price

+1.9%(1Y)
1M
-9.1%
3M
-20.1%
6M
-28.3%
YTD
-30.2%
1Y
-4.4%
3Y
+25.0%
5Y
-88.3%

Pipeline Summary

46 total trials
33
Phase 1
13
Phase 2
1
Phase 3
0
Phase 4
Completed: 38Terminated: 4Recruiting: 3Unknown: 1

Active Trials (3)

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults
NCT07540910Chronic Inducible Urticaria
Phase 1Recruiting
Enrollment: 98 participants
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
NCT07908381RSV
Phase 2Phase 3Recruiting
Enrollment: 860 participants
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
NCT07482657RSV Infection
Phase 2Recruiting
Enrollment: 150 participants

Key Facts

Market Cap$320.4M
Employees120 (-8% YoY)
CEOJay R. Luly
IPO DateMar 21, 2013
Beta0.96
52-Week Range$10.05 – $17.15
Avg Volume232,180
ExchangeNASDAQ
Websiteenanta.com

Ownership

Float95.3%
Shares Outstanding29.1M

Recent Insider Trades

Rottinghaus Scott T.TAX W/H
Aug 8, 20261,467 shares @ $13.34
Vance TerryAWARD
Mar 11, 202620,000 shares @ $14.17
Russell LesleyAWARD
Mar 11, 202620,000 shares @ $14.17
Peterson KristineAWARD
Mar 11, 202620,000 shares @ $14.17
Hata Yujiro SAWARD
Mar 11, 202620,000 shares @ $14.17

Peers

ASMBAssembly Biosciences, Inc.
$415.8M
AVIRAtea Pharmaceuticals, Inc.
$345.7M
CRBUCaribou Biosciences, Inc.
$48.1M
FHTXFoghorn Therapeutics Inc.
$111.1M
IMRXImmuneering Corporation
$238.3M
NAUTNautilus Biotechnolgy, Inc.
$284.0M
PRLDPrelude Therapeutics Incorporated
$287.3M
PYXSPyxis Oncology, Inc.
$105.2M

Recent News

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 4, 2026 · businesswire.com
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D.
Oct 28, 2026 · businesswire.com
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
Oct 26, 2026 · businesswire.com
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Oct 13, 2026 · businesswire.com
Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)
Oct 6, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:09 AM